Does ovarian-cancer clone diversity predict death?
In 14 women with high-grade serous ovarian cancer, high clonal expansion predicted worse PFS (10.1 vs 12.7 mo) and OS (23.5 vs 42.6 mo); an NF1-deleted relapse clone was already detectable before chemotherapy.
Source
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis
Study at a glance
- Design
- Cohort — Phylogenetic MEDICC analysis of spatially/temporally separated HGSOC samples from women receiving platinum chemotherapy (CTCR-OV03/04)
- N
- N=14 · 135 samples from 14 patients in the phylogenetic/survival analysis; 177 arrays from 18 patients profiled, 17 remaining after QC
- Population
- Women with high-grade serous ovarian cancer on platinum-based chemotherapy in CTCR-OV03/04
- Outcome
- Clonal-expansion (CE) index vs progression-free and overall survival; origin of relapse clones
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Used MEDICC on whole-genome copy-number profiles from 135 spatially and temporally separated samples in 14 HGSOC patients on platinum therapy (CTCR-OV03/04; median follow-up 31 mo). Dichotomized clonal expansion (CE) at the median and related it to PFS/OS; digital PCR tracked an NF1 deletion at relapse.
What they found
Median CE was 0.74 (IQR 0.66–1.15). CE-high tumors had PFS 10.1 vs 12.7 mo (p=0.009) and OS 23.5 vs 42.6 mo (p=0.003); CE-high remained independently prognostic. Bootstrapped HRs were 7.1 (PFS) and 11.4 (OS). An NF1 deletion marking relapse was already 5% and 26% of pre-treatment samples.
The limits
What it doesn't show
n=14 cannot precisely size the hazard; CE as a continuous variable was not significant in multivariable models, so the median split is a small-cohort signal, not a ready clinical test.
Key terms
- HGSOC
- High-grade serous ovarian cancer, typically TP53-mutant with extensive copy-number change.
- Clonal expansion (CE)
- MEDICC index of how much genomes cluster into expanding subclones; high CE tracked shorter survival.
- MEDICC
- Minimum Event Distance for Intra-tumour Copy Number Comparisons—algorithm for phylogenetic distances from copy number.
- NF1
- Tumour-suppressor gene; a subclonal NF1 deletion expanded during chemotherapy and dominated relapse.
- PFS
- Progression-free survival from pathology date to RECIST/CA125/symptomatic progression.
- TH index
- Temporal heterogeneity: mutational-landscape distance between biopsy and surgery samples during neoadjuvant treatment.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Phylogenetic analysis used samples from:
Common questions
How many patients/samples in the main analysis?
135 samples from 14 patients (177 arrays from 18 profiled).
CE-high survival?
PFS 10.1 vs 12.7 mo; OS 23.5 vs 42.6 mo.
Was the NF1 relapse clone new?
No—already 5% and 26% in pre-treatment samples.
Median follow-up?
31 months (IQR 22–46).
More on Oncology outcomes